Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Valerio Therapeutics (C4X) Stock Price & Analysis

C4X Stock Chart & Stats

€0.45€0.05(11.41%)
At close: 5:30 PM GMT+1
EUR 0.4EUR 0.6EUR 0.820 Jul3 Aug17 Aug31 Aug7 Sep28 Sep12 Oct
Day’s Range
EUR 0.45 - EUR 0.50
52-Week Range
EUR 0.06 - EUR 0.93
Previous Close
EUR 0.40
Volume
0
Average Volume (3M)
783
Market Cap
EUR 269.62M
Enterprise Value
EUR 77.01T
Total Cash (Recent Filing)
EUR 656.00K
Total Debt (Recent Filing)
EUR 12.84M
Price to Earnings (P/E)
―
Beta
0.60
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Recovery

The sharp 2025 revenue rebound indicates improving activity across Valerio Therapeutics’ development programs after a stagnant prior year. If maintained, stronger revenue can support research investment, improve operating leverage, and provide a more durable base for future partnering or financing opportunities.

Gross Margin

Sustained gross margins of roughly 67–71% are favorable for a clinical-stage biotechnology model because incremental development-related revenue can retain meaningful contribution after direct costs. Maintaining this profile would improve the economics of future collaborations, licensing income, or eventual product commercialization.

Cash Flow Improvement

The return to positive operating and free cash flow in 2025 marks a meaningful improvement from several years of sizable cash burn. Although not yet proven consistent, internally generated cash can reduce near-term dependence on external financing and help fund ongoing oncology research activities.

Bears Say

Persistent Net Losses

Valerio Therapeutics remains loss-making despite the 2025 revenue improvement, showing that current activities have not yet produced consistent earnings power. Continued net losses can consume capital, limit financial resilience, and require additional funding before oncology programs generate substantial partnering or commercial returns.

High Leverage

Debt materially exceeds the company’s equity base, leaving Valerio Therapeutics with constrained financial flexibility. Elevated leverage can increase financing pressure, reduce room to absorb setbacks in clinical development, and make it harder to allocate capital between research programs and balance-sheet needs over the next several quarters.

Volatile Cash Generation

The 2025 cash-flow improvement has not yet demonstrated durability because free cash flow was highly volatile and fell sharply versus the preceding period as reported. A return to heavier research spending or renewed cash burn could therefore recreate dependence on equity issuance or other external financing.

Valerio Therapeutics News

C4X FAQ

What was Valerio Therapeutics’s price range in the past 12 months?
Valerio Therapeutics lowest stock price was €0.06 and its highest was €0.93 in the past 12 months.
What is Valerio Therapeutics’s market cap?
Valerio Therapeutics’s market cap is €269.62M.
When is Valerio Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Valerio Therapeutics’s earnings last quarter?
Valerio Therapeutics released its earnings results on Jul 09, 2025. The company reported -€0.001 earnings per share for the quarter.
Is Valerio Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Valerio Therapeutics pay dividends?
Valerio Therapeutics does not currently pay dividends.
What is Valerio Therapeutics’s EPS estimate?
Valerio Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valerio Therapeutics have?
Valerio Therapeutics has 587,615,970 shares outstanding.
What happened to Valerio Therapeutics’s price movement after its last earnings report?
Valerio Therapeutics reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went down -8.861%.
Which hedge fund is a major shareholder of Valerio Therapeutics?
Currently, no hedge funds are holding shares in DE:C4X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology